Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor

Abstract

Jay Edelberg is an MD PhD graduate of Duke University in Durham, North Carolina, USA and trained in clinical cardiology at the Beth Israel Deaconess Medical Center in Boston. From 1999 to 2006, Dr Edelberg served as CCU cardiologist and led the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiovascular stem cells and biomarkers of cardiac aging. In 2006, Dr Edelberg became Director of Cardiovascular Urogenital Biomarker research at GlaxoSmithKline. Two years later, he moved to Bristol-Myers Squibb and progressed to become the US medical lead for Eliquis (apixaban). He joined Sanofi in 2012 as Vice President and Head of the newly formed PCSK9 Development & Launch Unit, reporting to Elias Zerhouni, President, Global R&D and Hanspeter Spek, President, Global Operations, Sanofi. Over the years, Dr Edelberg has published more than 75 peer-reviewed publications and has participated in numerous research and peer-review committees, including those of the National Institutes of Health (NIH), American Heart Association (AHA) and the California Institute for Regenerative Medicine (CIRM). He currently sits on the American Federation for Aging Research Board of Directors and is a Section Editor for the journal Aging Cell.